LIXT News and Press, Lixte Biotechnology Holdings Inc. From 04/12/22

3 Penny Stocks to Watch Ahead of the Stock Market Open Today After a less than stellar day of trading penny stocks on April 11th, investors have high hopes for today. In the past few weeks, anyone who has traded either penny stocks or blue chips is no stranger to volatility. [...

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . ( Nasdaq: LIXT ), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI),...

Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers ( loss - of - function mutations) correlates with marked clinical benefit. PASA...

PASADENA, CA, March 16, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MedInvest Pharmaceutical and Biotechnology Investo...

PASADENA, CA, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( NASDAQ: LIXT ) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI) , Amsterdam, one of the world’s leading comprehensive cancer centers, and Sticht...

Penny stocks have earned a reputation for upholding the “wild west” of the stock market. In many cases, the underlying companies are early-stage businesses with a lot of growing to do. However, you can find opportunities within this niche if you know what you’re loo...

3 Penny Stocks to Add to Your Watchlist Today Following a bullish few weeks for penny stocks and blue chips, we are beginning to see signs of Omicron-related fears settle in. Yesterday, news came out showing that the U.S. had hit 1 million cases of Covid per day. And while we knew this ...

Outside research shows that in models of colorectal, triple- negative breast and pancreatic cancer , LB- 100 induces molecular changes that render the cancers more vulnerable ...

Lixte Biotechnology Holdings (LIXT +0.6%) announces that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgic...

PASADENA, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain ...